GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
23 août 2022 07h00 HE
|
GH Research PLC
DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
18 mai 2022 07h00 HE
|
GH Research PLC
DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
28 mars 2022 07h04 HE
|
GH Research PLC
DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and...
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
06 déc. 2021 07h10 HE
|
GH Research PLC
DUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
06 déc. 2021 07h00 HE
|
GH Research PLC
Primary endpoint met in Phase 2 part of clinical trial for GH001 in TRD 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p<0.0001) Secondary endpoints met Mean change...
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
23 sept. 2021 17h25 HE
|
GH Research PLC
DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...